Literature DB >> 1122685

Ticarcillin vs carbenicillin: clinical pharmacokinetics.

R D Libke, J T Clarke, E D Ralph, R P Luthy, W M Kirby.   

Abstract

The pharmacokinetic characteristics of ticarcillin, a semisynthetic penicillin more active than carbenicillin against Pseudomonas, were compared to those of carbenicillin in 12 healthy volunteers. Following an intravenous infusion of 2 gm in 5 min, there was a lower average serum level for ticarcillin (218 mug/ml) than for carbenicillin (301 mug/ml), but after 2 hr the differences were not significant. The biologic half-life of ticarcillin was slightly longer than that of carbenicillin (72 and 65 min, P smaller than 0.01) and its volume of distribution was larger (15.7 and 12.3 l, P smaller than 0.01). Eighty-six per cent of the dose of ticarcillin and 99 percent of the dose of carbenicillin was recovered in the urine in 24 hr. Similar but much less marked blood level differences were noted with 2 gm, 30-min infusions. An intravenous infusion of 1 gm/hr gave average steady-state blood levels of about 124 mug/ml for both antibiotics. Probenecid, administered 1 hr before the infusion, caused significant and similar increases in blood levels, half-lives, and volumes of distribution of the 2 antibiotics. Protein binding in 100 percent human serum was 50 percent and 65 percent for carbenicillin and ticarcillin, respectively. These relatively small but definite differences in the pharmacokinetics of ticarcillin and carbenicillin are not likely to be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122685     DOI: 10.1002/cpt1975174441

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

2.  Pharmacokinetics of ticarcillin-clavulanate in premature infants.

Authors:  Kevin M Watt; Christoph P Hornik; Stephen J Balevic; Gratias Mundakel; C Michael Cotten; Barrie Harper; Daniel K Benjamin; Ravinder Anand; Matthew Laughon; P Brian Smith; Michael Cohen-Wolkowiez
Journal:  Br J Clin Pharmacol       Date:  2019-03-06       Impact factor: 4.335

Review 3.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

4.  Comparative pharmacokinetics of low- and high-dose ticarcillin.

Authors:  B J Guglielmo; J F Flaherty; R Batman; S L Barriere; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.

Authors:  G L Jungbluth; D L Cooper; G D Doyle; G M Chudzik; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  Levels of carbenicillin, ticarcillin, cephalothin, cefazolin, cefamandole, gentamicin, tobramycin, and amikacin in human serum and interstitial fluid.

Authors:  J S Tan; S J Salstrom
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

7.  Determination of ticarcillin levels in serum by high-pressure liquid chromatography.

Authors:  V H Shull; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  Pharmacokinetics of ticarcillin in man.

Authors:  B E Davies; M J Humphrey; P F Langley; L Lees; B Legg; G A Wadds
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  In vitro interaction of aminoglycosides with beta-lactam penicillins.

Authors:  S M Wallace; L Y Chan
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

10.  Comparative activity in vitro of ticarcillin, BL-P1654, and carbenicillin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.